Rfa Lumbar Medial Branch denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for rfa lumbar medial branch are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Lumbar Medial Branch RFA as Not FDA-Approved

This denial category reflects a fundamental classification issue: radiofrequency ablation of the lumbar medial branch nerves is a procedure, not a drug or device requiring FDA pre-market approval in the way pharmaceuticals do. The equipment used — radiofrequency generators and cannulae — is FDA-cleared as a device category, but the specific technique of lumbar medial branch RFA does not require individual FDA approval of each clinical application. When Cigna issues a "not FDA-approved" denial for a procedure, it often reflects either a coding error, a misapplication of drug-approval logic to a procedure, or an internal policy classification that equates "not specifically FDA-approved" with "not proven."

## Why This Denial Is Appealable

This type of denial is strongly appealable because the underlying premise — that a surgical or interventional procedure must be FDA-approved in the same way a drug must be — is incorrect as applied to lumbar RFA. Your appeal should address the misclassification head-on, supported by your physician's explanation of the regulatory framework governing procedural interventions.

## Federal Appeal Rights

• Internal appeal: File under ERISA §503 (self-funded) or applicable state insurance law (fully-insured) within the deadline shown on the denial letter, typically 180 days.
• External review: ACA §2719 grants access to an independent review organization (IRO) after internal exhaustion, within approximately four months of the final internal denial. IROs apply objective clinical standards and are well-positioned to correct misclassifications.
• Expedited review: Request if delay creates urgent health risk; decision within 72 hours.

## Concrete Appeal Steps

1. Obtain Cigna's complete written rationale for the "not FDA-approved" determination — specifically, what approval status they believe is lacking. 2. Have your interventional pain physician write a letter clarifying that lumbar medial branch RFA is a physician-performed procedure using FDA-cleared equipment, not a drug or device subject to independent pre-market drug-approval requirements. 3. Request the specific Cigna medical policy or LCD (local coverage determination) being applied, if Cigna is acting as administrator for a government plan. 4. Submit the full documentation package before the internal-appeal deadline. 5. Escalate to IRO if the internal appeal does not resolve the misclassification.

## Documentation to Gather

• Physician clarification letter: A letter from your treating physician explaining the regulatory and clinical status of lumbar medial branch RFA as an established interventional procedure.
• Diagnosis confirmation: Clinical notes and imaging establishing the underlying diagnosis of facet-mediated lumbar pain.
• Diagnostic block records: Documentation that prerequisite diagnostic nerve blocks were performed and met the response criteria in Cigna's own policy.
• Prior-treatment history: Records of conservative care attempted before the RFA request, with dates and outcomes.
• Clinical severity documentation: Chart notes documenting functional impairment and the impact of undertreated pain.

## Criteria-Mapping Structure

For this denial type, the criteria-mapping serves double duty: first correcting the approval-status misclassification, then demonstrating clinical appropriateness.

| Appeal Argument | Supporting Evidence | |---|---| | RFA is a physician procedure, not a drug — FDA-cleared equipment used | Physician letter; equipment FDA 510(k) clearance category, if obtainable | | Cigna's own policy covers the procedure for the indicated use | Relevant language from Cigna's coverage policy, if coverage exists in policy | | Diagnostic block prerequisite met | Block procedure notes, documented relief | | Conservative care completed | Chronological treatment records |

Addressing the classification error first — before clinical facts — is the most efficient path to reversal on a not-FDA-approved denial for a procedural intervention.